Analysis of Circulating Tumor Markers in Blood - ALCINA 5

Launched by INSTITUT DU CANCER DE MONTPELLIER - VAL D'AURELLE · Jul 2, 2025

Keywords

ClinConnect Summary

This clinical trial is studying certain substances called circulating tumor markers that can be found in the blood of people with cancer, including lung cancer. These markers come from cancer cells and can help doctors learn more about the cancer’s presence, how it might behave, and how well treatments might work. The study aims to improve ways to detect and measure these markers, which could lead to better diagnosis and treatment decisions in the future.

People who might join the study are adults with a confirmed or suspected invasive tumor (meaning the cancer has the potential to spread), regardless of where the tumor is in the body or its stage. Participants need to be 18 years or older, able to give informed consent, and covered by the French Social Protection System. If a tumor biopsy (a sample of tumor tissue) is needed, the tumor must be easy to reach, and blood clotting tests should be normal without the use of blood-thinning medications. Pregnant or breastfeeding women, those who cannot be regularly followed up, or people with certain recent cancer histories are not eligible. Participants can expect blood tests and possibly a biopsy, helping researchers better understand tumor markers in the blood and how they relate to cancer.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Patient presenting an invasive tumoral pathology (proved or suspected), whatever is the location or the stage,
• • 2. 18 years old or higher ?
• • 3. Patient who has provided informed, written, and explicit consent,
• • 4. Patient affiliated with a French Social Protection System.
• In the case of a tumor biopsy:
• • 5. Tumor considered as accessible by biopsy,
• • 6. Normal hemostasis assessment (PT, APTT, platelets),
• • 7. No anticoagulant or antiaggregant treatment for the biopsy.
• Exclusion Criteria:
• • 1. Pregnant woman and/or breast-feeding,
• • 2. Patient whose regular follow-up is impossible for psychological, family, social or geographical reasons,
• • 3. Private persons of freedom or under guardianship,
• • 4. Patient with a history of other invasive cancers within the 5 years preceding inclusion.